Providing dissolved or crushed bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead) through an enteral tube can achieve viral suppression and may be a good option for hospitalized patients with HIV, according to new research presented at CROI 2025, in San Francisco (poster 704).
In a small study, some 89% of 19 patients were virally suppressed and in care within one year of receiving therapy in this manner, said study co-author Kayla Bey, a PharmD candidate